Back to results
US 2020/0268684 A1Published application
Composition for treating and preventing neurological diseases, neuroinflamation and alzheimer's disease
AssigneeHsrx Group, LLC
InventorsJoshua M COSTIN, John M WILLIAMS, Norman RELKIN, Dan LI
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to compositions and methods of use that include compounds that treat and prevent neurological disorders including Alzheimer's disease, neuroinflammation, and diseases and conditions associated with protein misfolding and/or protein aggregation.
Claims21
-20. (canceled)
A composition comprising a combination of:
- biomarker 1 having an accurate mass of 120.094 amu and having a relative abundance of at least 2.17%;
- biomarker 2 having an accurate mass of 134.110 amu and having a relative abundance of at least 0.31%;
- biomarker 6 having an accurate mass of 200.157 amu and having a relative abundance of at least 0.47%;
- biomarker 12 having an accurate mass of 232.146 amu and having a relative abundance of at least 2.38%;
- biomarker 3 having an accurate mass of 150.104 amu and having a concentration of at least 0.04% by weight;
- biomarker 4 having an accurate mass of 176.120 amu and having a relative abundance of at least 0.96%;
- biomarker 5 having an accurate mass of 192.091 amu and having a relative abundance of at least 1.74%;
- biomarker 7 having an accurate mass of 202.172 amu and having a relative abundance of at least 0.87%;
- biomarker 8 having an accurate mass of 204.188 amu and having a relative abundance of at least 0.30%;
- biomarker 9 having an accurate mass of 216.151 amu and having a relative abundance of at least 10.75%;
- biomarker 10 having an accurate mass of 218.203 amu and having a relative abundance of at least 4.00%;
- biomarker 11 having an accurate mass of 220.183 amu and having a relative abundance of at least 0.72%;
- biomarker 13 having an accurate mass of 234.162 amu and having a relative abundance of at least 3.52%;
- biomarker 14 having an accurate mass of 256.240 amu and having a relative abundance of at least 0.25%;
- biomarker 15 having an accurate mass of 308.105 amu and having a concentration of at least 1.50% by weight;
- biomarker 16 having an accurate mass of 338.115 amu and having a concentration of at least 1.67% by weight;
- biomarker 18 having an accurate mass of 372.157 amu and having a concentration of at least 0.88% by weight;
- biomarker 19 having an accurate mass of 450.261 amu and having a relative abundance of at least 0.61%;
- and
- curcumin and/or a functional derivative of curcumin,
- wherein each biomarker is found in Curcuma longa, and
- wherein the relative abundance is relative to 25 mg/ml salicylic acid spiked in 0.5 mg/ml of the composition dissolved in ethanol.
19 more elements
A composition comprising curcumin and/or a functional derivative of curcumin and one or more of:
- biomarker 1 having an accurate mass of 120.094 amu and having a relative abundance of at least 2.17%;
- biomarker 2 having an accurate mass of 134.110 amu and having a relative abundance of at least 0.31%;
- biomarker 6 having an accurate mass of 200.157 amu and having a relative abundance of at least 0.47%;
- biomarker 12 having an accurate mass of 232.146 amu and having a relative abundance of at least 2.38%;
- biomarker 3 having an accurate mass of 150.104 amu and having a concentration of at least 0.04% by weight;
- biomarker 4 having an accurate mass of 176.120 amu and having a relative abundance of at least 0.96%;
- biomarker 5 having an accurate mass of 192.091 amu and having a relative abundance of at least 1.74%;
- biomarker 7 having an accurate mass of 202.172 amu and having a relative abundance of at least 0.87%;
- biomarker 8 having an accurate mass of 204.188 amu and having a relative abundance of at least 0.30%;
- biomarker 9 having an accurate mass of 216.151 amu and having a relative abundance of at least 10.75%;
- biomarker 10 having an accurate mass of 218.203 amu and having a relative abundance of at least 4.00%;
- biomarker 11 having an accurate mass of 220.183 amu and having a relative abundance of at least 0.72%;
- biomarker 13 having an accurate mass of 234.162 amu and having a relative abundance of at least 3.52%;
- biomarker 14 having an accurate mass of 256.240 amu and having a relative abundance of at least 0.25%;
- biomarker 15 having an accurate mass of 308.105 amu and having a concentration of at least 1.50% by weight;
- biomarker 16 having an accurate mass of 338.115 amu and having a concentration of at least 1.67% by weight;
- biomarker 18 having an accurate mass of 372.157 amu and having a concentration of at least 0.88% by weight;
- and
- biomarker 19 having an accurate mass of 450.261 amu and having a relative abundance of at least 0.61%,
- wherein each biomarker is found in Curcuma longa, and
- wherein the relative abundance is relative to 25 mg/ml salicylic acid spiked in 0.5 mg/ml of the composition dissolved in ethanol.
18 more elements
Dependencies are inferred from the claim text.